Rivaroxaban-Induced Hemorrhage Associated with ABCB1 Genetic Defect.
-
Ing Lorenzini K
Division of Clinical Pharmacology and Toxicology, University Hospitals of Geneva Geneva, Switzerland.
-
Daali Y
Division of Clinical Pharmacology and Toxicology, University Hospitals of Geneva Geneva, Switzerland.
-
Fontana P
Division of Angiology and Haemostasis, University Hospitals of Geneva Geneva, Switzerland.
-
Desmeules J
Division of Clinical Pharmacology and Toxicology, University Hospitals of Geneva Geneva, Switzerland.
-
Samer C
Division of Clinical Pharmacology and Toxicology, University Hospitals of Geneva Geneva, Switzerland.
Published in:
- Frontiers in pharmacology. - 2016
English
We report a patient who presented a non-ST segment elevation myocardial infarction in the context of severe normocytic hypochromic anemia related to gastrointestinal bleeding, 3 months after switching anticoagulant from the vitamin K antagonist acenocoumarol to the direct oral anticoagulant rivaroxaban. High levels of both anti-Xa activity and rivaroxaban plasma concentrations were measured despite rivaroxaban withdrawal, suggesting reduced elimination/drug clearance. Estimated half-life was 2-3 times longer than usually reported. The patient is a homozygous carrier of ABCB1 variant alleles, which could have participated to reduced elimination of rivaroxaban. Furthermore, CYP3A4/5 phenotyping showed moderately reduced enzyme activity. Drug-drug interaction with simvastatin may have contributed to decreased rivaroxaban elimination. Although in the present case moderate acute renal failure probably played a role, more clinical data are required to elucidate the impact of ABCB1 polymorphism on rivaroxaban pharmacokinetics and bleeding complications.
-
Language
-
-
Open access status
-
gold
-
Identifiers
-
-
Persistent URL
-
https://sonar.ch/global/documents/169611
Statistics
Document views: 28
File downloads: